← Back to Home

AI-designed pulmonary fibrosis drug shows signs of “rejuvenation”: How much can aging clocks tell us?

Early clinical data on rentosertib show a younger predicted age profile in patients’ blood proteins. But the analysis of 42 people over 12 weeks cannot yet determine whether this reflects improvement in lung disease or a genuine effect of the drug on aging.

By SURL BioNews

When lung disease is treated, aging signals in the blood may also change. The experimental drug rentosertib, developed with AI assistance, has shown such clues in patients with idiopathic pulmonary fibrosis (IPF): researchers analyzed samples taken before and after treatment using six protein aging clocks and found an overall shift toward a younger predicted biological age. However, a decline in clock readings remains a long way from proving rejuvenation in humans.

The study, published September 7 in *Nature Biotechnology*, used serum data from the phase 2a trial NCT05938920. Developed by Insilico Medicine, rentosertib inhibits TNIK, a kinase associated with fibrosis; according to the company, AI contributed to target selection and small-molecule design. Its specific intended use is to treat IPF, while this analysis further explored whether treating the disease might also produce aging-related biological changes.

The original trial used a randomized, double-blind, placebo-controlled design, with a treatment period of 12 weeks. This protein analysis included 42 patients from that trial, with a mean age of 67.1 years, and tracked 2,841 serum proteins. Protein aging clocks feed combinations of protein concentrations into models to estimate physiological profiles associated with age or mortality risk; their readings are model predictions and cannot be directly converted into an amount of lifespan extension.

The six models generally showed similar trends, but responses varied by dose, time point, and clock. The group receiving 30 milligrams twice daily showed the most consistent signal at week 4; changes in the placebo group were smaller. Meanwhile, the group with the greatest improvement in lung function in the original trial received 60 milligrams once daily. This difference raises a new research question, but is insufficient to establish that aging signals and improvement in lung disease are independent of each other.

Changes at the protein level provided another clue: the study identified treatment-associated trajectories of change in 326 proteins, compared with two in the placebo group, involving processes such as fibrosis, metabolism, and stress responses. These findings may help researchers trace how the drug works. However, the different clocks all draw on protein data from the same patients, so agreement in direction does not amount to multiple independent clinical validations.

This is also where the limitations lie. With a small sample, short follow-up, and an analysis covering only some patients from the original trial, it is not yet possible to adequately distinguish antifibrotic effects from broader anti-aging effects, much less infer that healthy people would also benefit. The study’s authors include the company’s founder and several employees; the data have been deposited at the China National Center for Bioinformation under accession number OMIX008341 for examination in subsequent research.

The value of this work lies in demonstrating how exploratory aging-related measures can be incorporated into disease trials. Next, research must link changes in clock readings to functional changes that patients actually experience, disease progression, and long-term safety before the clinical significance of these blood signals can be determined. For rentosertib, the immediate task remains validating it as a candidate IPF therapy; anti-aging efficacy has yet to be established.

References

  1. AI Insider
  2. Insilico Medicine
  3. Bloomberg Law
  4. News-Medical